MedTrace Logo

Immunity After COVID-19 Vaccination

NCT04883164 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-05-12

No results posted yet for this study

Summary

The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination. Recent studies show that less than one-fifth of chronically immunosuppressed transplant recipients developed anti-receptor-binding domain antibodies after the first dose of the Pfizer vaccine (Boyarski, 2021).

ood sampling at periodic intervals. These samples will be used to measure T-cell and antibody immunity to the COVID-19 coronavirus.

Conditions

  • Immunity to COVID-19

Interventions

OTHER

Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples

Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.

Sponsors & Collaborators

  • Plexision

    lead INDUSTRY

Principal Investigators

  • Ashok Reddy, BE · Plexision

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883164 on ClinicalTrials.gov